Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

clinpract-15-00211-v2.pdf (204.57 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-11-17

Llicència de publicació

cc-by (c) Varela Gonzalez-Aller, Javier et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224897

Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/clinpract15110211

Resum

Background/Objectives: Asparaginase (ASP)-based chemotherapy has substantially improved clinical outcomes in Epstein-Barr virus (EBV)-positive NK/T-cell lymphomas (NKTCL). However, as a bacterial-derived enzyme, ASP is frequently associated with immune-mediated adverse events, particularly hypersensitivity reactions (HSRs), which may compromise both treatment efficacy and patient safety. This report presents a case of an ASP-related HSR and reviews the incidence within our institutional cohort. Detailed Case Description: A 60-year-old female presented an immediate Grade 2 HSR during her second PEG-asparaginase infusion, with pruritus, vomiting, and presyncope. The infusion was discontinued, and she was subsequently transitioned to crisantaspase-an alternative formulation-which was well tolerated without further adverse events. She remains disease-free to date. A retrospective review of institutional records (2015-2025) identified six patients with NKTCL treated with ASP-containing chemotherapy. The incidence of HSRs in this cohort was 1 of 6 (16.7%). Conclusions: As in acute lymphoblastic leukemia, HSRs to asparaginase remains a major challenge in the management of NKTCL with potential implications for treatment safety and efficacy. The establishment of standardized, consensus-based criteria for the diagnosis, classification, and management of ASP-related HSRs is urgently needed to optimize patient outcomes.

Matèries

Immunosupressió, Leucèmia limfocítica crònica, Cèl·lules K

Matèries (anglès)

Immunosuppression, Chronic lymphocytic leukemia, Killer cells

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VARELA GONZALEZ-ALLER, Javier, et al. Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas. Clinics and Practice. 2025. Vol. 15, num. 11, pags. 211. ISSN 2039-7283. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/224897

Exportar metadades

JSON - METS

Compartir registre